Orgenesis Inc. (ORGS) Cash Flow Statement
Where ORGS’s cash came from and went, 2024
December 31, 2024 · U.S. dollars- Cash from operations
- −$17.1M
- Capital expenditures
- $263,000 25.4% of revenue
- Free cash flow
- −$17.3M −1,675.3% margin
- Returned to shareholders
- —
- Change in cash
- −$752,000 cash at year-end $687,000
Cash from operations
−$17.1M
Capital expenditures
−$263,000
Net borrowing (repayment)
+$5.9M
Shares issued
+$2.6M
Other financing
+$7.5M
Currency & other
+$628,000
Change in cash
−$752,000
Drawn to scale: where the cash came from and how it was used. Hover for values.
ORGS operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
ORGS cash flow trends, 2016–2024
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$3.8M2016 | −$17.1M2024 | — | |
| Capital expenditures | $1.4M2016 | $263,0002024 | −17.1%/yr | |
| Free cash flow | −$5.2M2016 | −$17.3M2024 | — | |
| Free cash flow margin | −81.4%2016 | −1,675.3%2024 | −1,593.9 pts | |
| Stock-based compensation | $2.9M2016 | $3.2M2024 | +1.2%/yr | |
| Share buybacks (net) | $02016 | $107,0002022 | — | |
| Capex / revenue | 22.3%2016 | 25.4%2024 | +3.1 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ORGS cash flow by activity
OperatingInvestingFinancingChange in cash
ORGS net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
ORGS cash flow statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$48.2M | −$64.9M | −$12.2M | −$18.1M | $579,000 | −$26.0M | −$19.1M | −$19.1M | −$12.4M | −$9.2M |
| Depreciation & amortization | $2.1M | $1.6M | $2.0M | $1.9M | $1.4M | $3.8M | $2.6M | $2.6M | $2.6M | $2.9M |
| Stock-based compensation | $3.2M | $463,000 | $982,000 | $1.7M | $19.9M | $5.7M | $4.4M | $4.4M | $3.4M | $2.9M |
| Change in working capital | $1.7M | $36.6M | −$20.0M | −$15.4M | −$3.3M | $3.3M | −$1.4M | −$1.4M | $1.3M | $800,000 |
| Other non-cash items | $24.1M | $11.4M | $4.3M | $3.0M | −$96.7M | $19,000 | −$2.2M | −$2.2M | $1.3M | −$1.2M |
| Cash from operating activities | −$17.1M | −$14.8M | −$24.9M | −$26.9M | −$78.0M | −$13.2M | −$15.7M | −$15.7M | −$3.8M | −$3.8M |
| Investing activities | ||||||||||
| Capital expenditures | −$263,000 | −$2.1M | −$12.4M | −$7.9M | −$1.5M | −$12.1M | −$5.6M | −$5.6M | −$975,000 | −$1.4M |
| Investments (net) | — | −$12.1M | −$14.1M | −$12.4M | $105.6M | −$13.8M | — | −$6.3M | −$3.4M | −$1.5M |
| Acquisitions & other investing | — | $10.5M | $12.4M | $7.9M | $1.5M | $12.1M | −$712,000 | $5.6M | $975,000 | $1.4M |
| Cash from investing activities | — | −$3.7M | −$14.1M | −$12.4M | $105.6M | −$13.8M | −$6.3M | −$6.3M | −$3.4M | −$1.5M |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | −$106,000 | — | — | — | — | — | — |
| Share repurchases & issuance (net) | — | — | −$107,000 | −$1.0M | −$250,000 | $13.2M | — | $17.4M | $5.3M | $1.5M |
| Net borrowing (repayment) | $5.9M | $3.3M | $16.8M | −$1.0M | −$2.6M | $10.9M | $2.4M | $1.4M | $719,000 | $635,000 |
| Shares issued | $2.6M | $5.5M | $2.2M | $1.9M | $8.7M | $8.4M | $0 | $17.4M | $0 | $0 |
| Other financing | $7.5M | $4.8M | $20.7M | $106,000 | $0 | −$8.4M | $32.7M | −$1.1M | $2.3M | $0 |
| Cash from financing activities | $16.0M | $13.6M | $39.6M | −$106,000 | $5.9M | $24.1M | $35.1M | $35.1M | $8.4M | $2.1M |
| Summary | ||||||||||
| Net change in cash | −$752,000 | −$4.9M | $395,000 | −$39.6M | $33.5M | −$3.0M | $12.9M | $12.9M | $2.6M | −$3.3M |
| Cash at end of period | $687,000 | $1.5M | $6.4M | $6.0M | $45.6M | $12.0M | $16.5M | $16.5M | $3.5M | $891,000 |
| Free cash flow | −$17.3M | −$16.9M | −$37.3M | −$34.7M | −$79.6M | −$25.3M | −$21.2M | −$21.2M | −$4.8M | −$5.2M |
| Free cash flow margin | −1,675.3% | −3,194.9% | −103.7% | −97.8% | −1,039.9% | −76.2% | −113.8% | −113.8% | −47.7% | −81.4% |
| Capex / revenue | 25.4% | 395.5% | 34.5% | 22.2% | 19.9% | 36.5% | 29.8% | 29.8% | 9.7% | 22.3% |
| Operating cash flow / net income | — | — | — | — | −134.79 | — | — | — | — | — |
| Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$20.4M | −$10.0M | −$8.9M | −$9.8M | −$44.3M | −$12.7M | −$3.7M | −$4.2M | −$1.3M | −$1.4M | −$5.5M | −$4.0M |
| Depreciation & amortization | $463,000 | $538,000 | $706,000 | $381,000 | $194,000 | $191,000 | $597,000 | $578,000 | $515,000 | $488,000 | $501,000 | $474,000 |
| Stock-based compensation | $639,000 | $2.2M | $624,000 | $312,000 | $76,000 | $76,000 | $152,000 | $159,000 | $288,000 | $194,000 | $232,000 | $268,000 |
| Change in working capital | $2.9M | $910,000 | −$3.1M | $2.2M | $42.3M | $1.3M | −$3.2M | $12.6M | −$12.3M | −$5.0M | −$2.5M | −$232,000 |
| Other non-cash items | $14.3M | $1.7M | $4.8M | $2.4M | $1.2M | $9.9M | $149,000 | −$16.4M | $2.0M | $729,000 | $819,000 | $695,000 |
| Cash from operating activities | −$2.1M | −$4.6M | −$5.9M | −$4.4M | −$502,000 | −$1.2M | −$5.9M | −$7.2M | −$10.8M | −$5.0M | −$6.4M | −$2.8M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | −$58,000 | −$1,000 | −$204,000 | −$55,000 | −$300,000 | −$511,000 | −$1.3M | −$5.4M | −$2.6M | −$3.5M | −$902,000 |
| Investments (net) | — | $142,000 | −$1,000 | −$68,000 | −$68,000 | −$843,000 | −$1.5M | −$1.3M | −$1.3M | −$2.6M | −$3.2M | — |
| Acquisitions & other investing | — | $58,000 | $1,000 | $204,000 | — | — | $511,000 | — | $77,000 | $2.6M | $3.5M | −$711,000 |
| Cash from investing activities | — | $142,000 | −$1,000 | −$68,000 | — | — | −$1.5M | — | −$6.7M | −$2.6M | −$3.2M | −$1.6M |
| Financing activities | ||||||||||||
| Dividends paid | — | — | — | — | — | — | −$100,000 | — | — | — | — | — |
| Share repurchases & issuance (net) | — | — | — | −$100,000 | $100,000 | — | −$100,000 | — | $0 | $0 | $0 | — |
| Net borrowing (repayment) | $1.4M | $3.6M | $528,000 | $349,000 | — | — | −$14,000 | — | −$14,000 | $8.1M | $8.7M | — |
| Shares issued | $0 | $28,000 | $168,000 | $2.4M | $2.4M | $1.0M | $100,000 | $3.4M | $3.4M | $2.2M | $0 | $0 |
| Other financing | −$16,000 | $790,000 | $5.8M | $1.0M | −$1.2M | −$4.4M | $5.0M | $2.5M | −$3.9M | −$1.1M | $2.2M | $1,000 |
| Cash from financing activities | $1.4M | $4.4M | $6.5M | $3.6M | $1.2M | −$3.4M | $4.9M | $5.9M | −$517,000 | $9.2M | $10.9M | $1,000 |
| Summary | ||||||||||||
| Net change in cash | −$407,000 | −$34,000 | $591,000 | −$914,000 | $690,000 | −$438,000 | −$2.5M | −$2.6M | $1.9M | $1.7M | $1.1M | −$4.4M |
| Cash at end of period | $687,000 | $1.1M | $1.2M | $565,000 | $1.5M | $789,000 | $1.2M | $3.7M | $6.4M | $4.5M | $2.8M | $1.6M |
| Free cash flow | −$2.1M | −$4.7M | −$5.9M | −$4.6M | −$557,000 | −$1.5M | −$6.4M | −$8.5M | −$16.2M | −$7.6M | −$9.9M | −$3.7M |
| Free cash flow margin | −697.0% | −1,351.0% | −2,401.6% | −3,294.3% | — | −1,346.4% | −92.1% | −121.0% | −119.0% | −94.8% | −137.0% | −51.2% |
| Capex / revenue | 0.0% | 16.7% | 0.4% | 144.7% | — | 272.7% | 7.3% | 18.2% | 40.0% | 32.8% | 47.9% | 12.5% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
ORGS cash generation
In fiscal 2024 (ended December 31, 2024), Orgenesis generated -$17.1 million of cash from operations and spent $0.3 million on capital expenditures, leaving free cash flow of -$17.3 million, −1,675.3% of revenue. Cash and equivalents fell by $0.8 million over the year.
Related: ORGS income statement, ORGS balance sheet. See the ORGS stock overview for the latest quote and news.
ORGS cash flow FAQ
What is Orgenesis's free cash flow?
Orgenesis's free cash flow was -$17.3 million in fiscal 2024: -$17.1 million of operating cash flow minus $0.3 million of capital expenditures It was -$16.9 million a year earlier..
How much cash does Orgenesis generate from operations?
Orgenesis generated -$17.1 million of cash from operating activities in fiscal 2024.
How much does Orgenesis spend on capital expenditures?
Orgenesis spent $0.3 million on capital expenditures in fiscal 2024, 25.4% of revenue, compared with $2.1 million the year before.